Latest news with #Delve
Associated Press
07-05-2025
- Health
- Associated Press
New Data Show Delve Bio's Metagenomic Platform Accurately Identifies Viruses and Their Subtypes With a Single Test
BOSTON--(BUSINESS WIRE)--May 7, 2025-- Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data showing that its groundbreaking infectious disease test, Delve Detect, is also capable of viral subtyping for select pathogens from sequence data analyzed through its proprietary bioinformatics pipeline, Delve Decide. The data will be presented at the Pan American Society for Clinical Virology (PASCV) Annual Meeting on May 8, 2025, in Clearwater, Florida. 'Identifying a pathogen is only the first part of the story. Knowing detailed information about the virus can signal to a physician whether a patient's infection is linked to an outbreak, carries unusual risks, or requires a change in management – crucial information when treating a patient with serious infections,' said Brian O'Donovan, Ph.D., head of bioinformatics at Delve Bio. 'Our study demonstrates mNGS has the potential to provide this information as part of routine testing, eliminating the need for sequential testing and subtyping that may delay patient care.' In the study, sequencing data generated by Delve Detect were compared to a specialized database of reference genomes. The study determined viral subtypes and phylogenetic classifications delivered by the Delve Decide bioinformatics platform across a number of viruses, including St. Louis encephalitis virus, enterovirus, West Nile virus, varicella-zoster virus and HIV, and described concordance with independent testing methods. 'Metagenomics is a game-changer for diagnosing infectious diseases, delivering meaningful, detailed information about the cause of a patient's infection through a single, straightforward test,' added Steve Miller, M.D., Ph.D., chief medical officer at Delve Bio. 'This study demonstrates that Delve Detect can deliver information that can impact management based on viral subtyping information and improve patient care.' The data will be presented at the meeting in poster No. 31, Rapid, Simultaneous Viral Pathogen Detection, Subtyping and Strain Differentiation Through Unbiased Metagenomic Sequencing With Delve Detect CSF on May 8 at 2:45 p.m. The study is part of the company's overall presence at the meeting, which also includes a presentation titled Metagenomic Next Generation Sequencing for CNS Infection by Delve co-founder Charles Chiu, M.D., Ph.D., professor of laboratory medicine and medicine/infectious diseases at University of California San Francisco (UCSF) today, Wednesday, May 7, at 6 p.m. Delve Detect was built on technology developed at UCSF, which is exclusively licensed to Delve Bio. Delve Detect is Delve Bio's flagship metagenomic testing service, providing comprehensive pathogen detection with a 48-hour turnaround time after sample receipt and including access to Delve's Clinical Microbial Sequencing Board, an on-call team of infectious disease experts who review results in clinical context. About Delve Bio, Inc. Delve Bio is a metagenomic next-generation sequencing (mNGS) company that empowers laboratories and clinicians with the insights they need to confidently diagnose routine and rare infectious diseases, thereby minimizing the impact of harmful pathogens on humanity. By leveraging its unbiased, pathogen-agnostic mNGS platform, Delve Bio is able to identify a wide range of pathogens with a single test. Founded by world leaders in genomics and infectious disease Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti, and Matthew Meyerson, the company is backed by top institutional investors including Perceptive Xontogeny Venture Fund II, Section 32, and GV, along with leading individual investors. For more information, visit View source version on CONTACT: Company ContactAmy Wong Senior Director of Marketing and Business Development, Delve Bio Email:[email protected] ContactJulie McKeough 42 North for Delve Bio Email:[email protected] KEYWORD: UNITED STATES NORTH AMERICA FLORIDA MASSACHUSETTS INDUSTRY KEYWORD: AIDS HEALTH INFECTIOUS DISEASES GENETICS HEALTH TECHNOLOGY BIOTECHNOLOGY SOURCE: Delve Bio, Inc. Copyright Business Wire 2025. PUB: 05/07/2025 07:32 AM/DISC: 05/07/2025 07:31 AM
BBC News
13-04-2025
- General
- BBC News
Restoration of RAF West Raynham will support veterans
A former RAF station headquarters is being restored to help support veterans in West Raynham closed in 1994 and its buildings became derelict until the Veterans' Service took over the building in have begun to restore the Grade II listed 1930s block and surrounding gardens, which are now used to help reduce social isolation and provide Delve, chair of trustees of the Veterans' Central, said: "We were looking for a veterans' hub, somewhere where veterans can come together for a breakfast, work together and socialise, removing social isolation and giving a sense of purpose." Mr Delve, who served as an RAF navigator on the Canberra and Tornado aircraft, said he and other volunteers at the RAF Marham heritage centre decided to restore the West Raynham station headquarters."Once it closed it went into a ten year period of care and maintenance, which meant no care and no maintenance, so all the buildings and the base started deteriorating," he said."Thirty years on it's been overgrown, things stolen and broken windows - that was the condition of what was a very important airfield in Norfolk for many years."When we first opened the door in late 2022, putting the live and dead animals to one side; the broken glass and water running down the walls, the veterans went: 'This is really good. We can do this', and in March 2023 we started." 'It's about people' Mr Delve estimated that some 26,000 hours of volunteer labour put the group six months ahead of what he said would be a seven-year project, transforming buildings and clearing gardens that had been 12ft (3.6m) high with he said they relied heavily on volunteers for labour and local businesses with materials, including a new kitchen and a greenhouse provided by firms that operate on part of the West Raynham average working day would see between 15 and 20 volunteers on site - and about a third had no military connection but wanted to join the team. He said he "got to know a lot of the old boys and girls from way back" through his interest as a squadron historian."I found their stories very interesting and had a passion for RAF history," he added."But [it is] the people involved - it's not about aeroplanes or buildings, it's about people. It's very much a people-driven project to make it work. "One of our aims is to give veterans a purpose, a reason to get up that day, go and do something, work with a team, have a bit of banter and a few slices of cake and a couple of cups of tea and feel you've achieved something with the day instead of sitting there doing nothing."The other is social isolation, so we do a monthly breakfast and a monthly lunch for veterans and they are all free at the point of delivery. "We are very lucky that local companies are starting to sponsor those lunches and breakfasts." Follow Norfolk news on BBC Sounds, Facebook, Instagram and X.
Associated Press
07-04-2025
- Health
- Associated Press
Delve Bio to Present on Metagenomic Next Generation Sequencing (mNGS) at the American Academy of Neurology 2025 Annual Meeting
Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, will share data about its groundbreaking mNGS test, Delve Detect, at the 2025 American Academy of Neurology Annual Meeting today in San Diego. With the ability to identify more than 68,000 pathogens with a single test, Delve's mNGS technology delivers greater diagnostic yield over conventional methods of diagnosing meningitis and encephalitis. 'Diagnosing meningitis and encephalitis has historically required running test after test as physicians try to determine which pathogen is causing a patient's infection. In more than half of those cases, the cause is never found,' said Steve Miller, M.D., Ph.D., chief medical officer at Delve Bio. 'By using a metagenomic test, clinicians can detect viruses, bacteria, parasites, and fungi in just one test. It's an approach with more than seven years of real world evidence behind it showing mNGS outperforms traditional testing methods by over 20%, helping solve complex cases faster.' At this year's AAN Annual Meeting, Delve is presenting its mNGS assay and the technology behind Delve Detect. The backbone of Delve's mNGS platform is Delve Decide, which enables sequence matching of DNA and RNA to a curated database of over 68,000 pathogens through robust bioinformatic analysis, validated QC metrics, dynamic filtering, and visualization of high-quality reads; the results receive expert clinical interpretation to deliver comprehensive microbial analysis impossible through conventional testing. The strength of Delve's approach has been demonstrated through data from more than 4,800 patients tested at the University of California San Francisco (UCSF) over seven years – the largest study of its kind. The study found mNGS identified more pathogens than all other traditional methods (culture, antigen testing, PCR, and serology) combined. Published in Nature Medicine, the data showed mNGS detected pathogens in 14.4% of samples, representing 437 unique pathogen species, including DNA and RNA viruses, bacteria, fungi, and parasites. Among a subset of more than 1,000 patients treated at UCSF, 21.8% (48 of 220) of infections were identified by mNGS alone. Delve Detect is the company's flagship testing service, providing comprehensive test results with a 48-hour turnaround time after sample receipt and access to Delve's Clinical Microbial Sequencing Board, an on-call team of infectious disease experts to review results in clinical context. Delve Detect was built on technology developed at UCSF, which is exclusively licensed to Delve Bio. About Delve Bio, Inc. Delve Bio is a metagenomic next-generation sequencing (mNGS) company that empowers laboratories and clinicians with the insights they need to confidently diagnose routine and rare infectious diseases, thereby minimizing the impact of harmful pathogens on humanity. By leveraging its unbiased, pathogen-agnostic mNGS platform, Delve Bio is able to identify a wide range of pathogens with a single test. Founded by world leaders in genomics and infectious disease Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti, and Matthew Meyerson, the company is backed by top institutional investors including Perceptive Xontogeny Venture Fund II, Section 32, and GV, along with leading individual investors. For more information, visit Amy Wong Senior Director of Marketing and Business Development, Delve Bio Media 42 North for Delve Bio INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES NEUROLOGY CLINICAL TRIALS RESEARCH SCIENCE SOURCE: Delve Bio, Inc. Copyright Business Wire 2025. PUB: 04/07/2025 07:27 AM/DISC: 04/07/2025 07:26 AM
